NCT06902025View on ClinicalTrials.gov

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia

NANot yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
B-ALL
Interventions
DRUG

JY231 Injection

Patients were enrolled and given a single dose of JY231 injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 15 years.

Trial Locations (1)

310003

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

He Huang

OTHER

NCT06902025 - JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia | Biotech Hunter | Biotech Hunter